Kate Middleton Shares New Message After Dropping Out of Royal Ascot Appearance
The Princess of Wales, 43, praised them for lifting the spirits of children and families "through life, death and beyond"
Her June 20 message, as Children's Hospice Week draws to an end, came six months after she took on the role of patron to a hospice in South WalesKate Middleton is showing her support for kids' hospices in a poignant week.
In a new message issued on Friday, June 20, the Princess of Wales praised how hospices 'lift the spirits' and support seriously ill children and their families through 'life, death and beyond.'
She said it was an 'immense privilege' seeing the work up close of two hospices, with East Anglia's Children's Hospices and Tŷ Hafan Children's Hospice, during her visits as their patron.
It came in a week when Princess Kate, 43, dropped out of an expected visit to the Royal Ascot race meeting on Wednesday. Kate is still managing her return to public-facing duties amid her recovery from cancer treatment.
In her message on June 20, Kate wrote, 'No parent expects to hear that their child has a serious health condition that could shorten their life. Sadly, this is the reality faced by thousands of families across the country, leaving them heartbroken, fearful of the future and often desperately isolated."
'Being able to access the support of one of the U.K.'s 54 children's hospices means they don't have to face that future alone," she added.
'As Patron of East Anglia's Children's Hospices and Tŷ Hafan Children's Hospice in South Wales, I have the immense privilege of seeing for myself the extraordinary work of our children's hospices," she said. "Lifting spirits through laughter, fun and play, as well as listening, holding, caring and sharing, they support children and families through life, death and beyond."
"This Children's Hospice Week, I hope you will join me in celebrating the life-changing work they do and thanking them for the vital care they provide to children and families experiencing the most challenging times," Kate concluded.
Support for children's hospices has been an ever-present part of Princess Kate's public work since she started in public life soon after marrying Prince William in 2011. She has also visited hospices around the world during her overseas tours.
During Children's Hospice Week, which ends on June 22, the charity Together for Short Lives brings together the vital services to celebrate the incredible work they do for seriously ill children and their families.
Kate made her first visit to Tŷ Hafan in January, spending more time than she was scheduled, crouching down, talking to youngsters and their families and joining in with the games. Tŷ Hafan — which means "Haven House" in Welsh — is located in Sully, South Wales, and was built with the support of Prince William's late mother, Princess Diana.
Tracy Jones, the director of family well-being services who showed Kate around, said on the day of the visit in January, 'She immediately gravitated to the children and families — she spent quality time talking to every child and their parents.'
'It's been the most inspiring visit,' Jones added. 'She crouched down and was straightaway on the level of the children. If they were in a wheelchair, she crouched at that level. If they were on the floor, she would be at the level,' she continues. 'We were seriously impressed with how she could stay in a crouch, as it's not that comfortable!"
"She instinctively seemed to know where to touch a child that was going to provide the connection, but not cause any distress or startle a child. She was looking at the children, even if she was talking to the parent. It's what we do, as we're used to working with children who are nonverbal," she added.
Nick Carroll, CEO of Together for Short Lives, praised Kate's "ongoing support for Children's Hospice Week over many years [that] has helped to raise much-needed awareness of the life-changing work children's hospices do, every day of the year."
"Their extraordinary lifeline care for children with life-limiting and life-threatening illnesses enables families to make the most of their lives together, whether that's for years, months or only hours," he said. 'Together with all the children's hospices, we thank the Princess of Wales for her invaluable contribution.'
Irfon Rees, Chief Executive of Tŷ Hafan Children's Hospice, said in a statement on June 20, 'Her Royal Highness is clearly profoundly committed to the needs of children and young people, and in January, during her first visit to our hospice as our patron, her kindness and empathy were evident."
'Having HRH's support during Children's Hospice Week means that not only can we take time to celebrate the difference that children's hospices, including Tŷ Hafan, have made to the lives of so many families, but that we can also remind people of the importance of supporting their local children's hospice so that no family has to live their child's short life alone.'
Can't get enough of PEOPLE's Royals coverage? to get the latest updates on Kate Middleton, Meghan Markle and more!
Kevin Clements, Chief Executive of EACH, based in the area close to the Wales family's country home, Anmer Hall, in Norfolk, added, 'We're so incredibly grateful for The Princess' invaluable contribution as our dedicated Royal Patron. Her ongoing support and vast profile have projected our charity onto the global stage, and this latest message is a perfect way to mark Children's Hospice Week."
'It's a great opportunity to shine a light on the work of children's hospices generally, as well as giving us an opportunity to raise awareness and remind everyone of the need for public support, given we rely on donations for the majority of our income.'
Read the original article on People
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


TechCrunch
35 minutes ago
- TechCrunch
Tony Robbins' and Peter Diamandis' longevity company Fountain Life raises $18M
Eight years ago, orthopedic surgeon Dr. William Kapp attended a medical conference that changed his professional life. He had gone from a private practice doctor to co-founding a company that built critical care hospitals to then selling that company. It gave him an interest for both sides of healthcare: the medicine and business sides, he told TechCrunch. So he went to the annual conference hosted by famed physician-scientist Dr. Daniel Kraft to learn about new tech that could improve results while lowering costs. Dr. Peter Diamandis, founder and chairman of the XPRIZE Foundation, was on stage that year with Dr. Bob Hariri, a stem-cell pioneer and co-founder of several health techs like genomics company, Human Longevity, Kapp said. They discussed genomics, microbiomics, and new tech that wasn't part of mainstream medicine. Inspired, Kapp went back to his home town of Naples, Florida, and 'started a thing called Longevity Performance Center. The idea was to do early detection and then optimization of people's health,' he said. In March 2020, Diamandis (pictured above) and his buddy Tony Robbins heard of Kapp's center and visited. They had a stem cell startup called Fountain Therapeutics. Conversation soon turned toward a merger, and by October that year, the two companies became Fountain Life. Kapp remained CEO with both Diamandis and Robbins as his co-founders and board members. Today his board also includes Hariri as an adviser; Todd Wanek, CEO of Ashley Furniture Industries, as an investor; and wealthy Indian business mogul B.K. Modi as an investor as well. Techcrunch event Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital, Elad Gil — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $600+ before prices rise. Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $675 before prices rise. San Francisco | REGISTER NOW Fountain Life tells TechCrunch exclusively that it just raised an $18 million series B, led by EOS Ventures, with participation from most of the existing members of the board. Fountain previously raised an $80 million Series A and has raised about $108 million total, Kapp said. Longevity as a subject of serious study by the medical community is a new field. When Kapp (pictured below) first launched his center, 'We didn't know exactly what longevity meant,' he said. But over the last four or five years, much more research has been done. The first principle of longevity, he said, is 'don't die of anything stupid.' Therefore, Fountain Life's centers, of which there are four today, have a heavy focus on prevention screening, looking for illnesses and chronic conditions at their earliest stages when they tend to be asymptomatic. Blood tests and body scans gather data on over 100 biomarkers from liver fat to 'microbiome concentrations,' he said. The second principal is optimization, meaning improving those markers with scientifically validated treatments, he said. And the third principal is 'using the latest regenerative therapies under FDA trials,' to treat illness or achieve optimization. Screening tests may discover, for example, small intestinal bacterial overgrowth (SIBO), which, left untreated, may lead to certain cancers, he said. The solution, if caught early, is to restore microbiome balance with specific, prescribed microbiotics. Dr. William Kapp Image Credits:Fountain Life For Fountain's members, testing is repeated every quarter or so, and patients can track results and ask questions of an AI-powered app called Zori. But it's pricey, Kapp admitted. A full subscription costs $30,000 a year, and $10,000 will cover just the testing process and AI, but not ongoing tests and medical support. Still, Kapp remembers two stories that told him this work was on the right track. The wife of a Robbins fan bought a membership for her husband, and the tests caught early-stage, asymptomatic kidney cancer. The husband is now cancer-free. When global hotelier Sam Nazarian was exploring a partnership with Fountain to put longevity centers in luxury hotels, Nazarian did Fountain's tests and found a brain aneurysm. They successfully treated it, Nazarian has publicly said. Kapp says the new funding will allow the company to open more centers. In addition to Naples; Westchester, New York; Orlando; and Dallas, a center in Houston will open in December. Centers in Los Angeles and Miami are planned for Q2 of 2026. He hopes to solve the affordability issue by working on 'clinic development' where Fountain trains medical facilities on its methodologies. Kapp says that as the tech and expertise become more widely available, this will drive down costs for access. Fountain is not the only doctor-driven longevity testing startup. Famed functional health doctor Mark Hyman has a company called Function Health. It offers a package of about 160 blood tests, with follow-up tests every three to six months, for a $500/year membership (with additional fees for additional blood tests). Its platform similarly analyzes and tracks test results, although it doesn't do full body scans or offer direct access to physicians.


The Verge
an hour ago
- The Verge
Some doctors got worse at detecting cancer after relying on AI
We've heard about upskilling and re-skilling due to AI — but how about de-skilling? A new study published this week found that doctors who frequently use AI to detect cancer in one medical procedure got significantly worse at doing so. The researchers set out to discover whether continuous exposure to AI impacted doctors' behavior when conducting colonoscopy, so they decided to assess 'how endoscopists who regularly used AI performed colonoscopy when AI was not in use.' The answer: Not so hot. The rate was about six percentage points lower. The study was published in The Lancet Gastroenterology & Hepatology journal by medical professionals and researchers in countries including Poland, Norway, Sweden, the U.K., and Japan. It followed doctors at four endoscopy centers in Poland, which were part of a trial program focusing on AI's use in colonoscopy for potential cancer prevention. It raises questions about the use of AI in healthcare, when it helps and when it could hurt. Last week, The Verge reported on a Google healthcare AI model's instance of potentially hallucinating a body part and where medical professionals think the industry will go from from this author will be added to your daily email digest and your homepage feed. See All by Hayden Field Posts from this topic will be added to your daily email digest and your homepage feed. See All AI Posts from this topic will be added to your daily email digest and your homepage feed. See All Health Posts from this topic will be added to your daily email digest and your homepage feed. See All News Posts from this topic will be added to your daily email digest and your homepage feed. See All Science
Yahoo
2 hours ago
- Yahoo
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
The Saudi Arabia Osteoporosis Drugs Market is projected to grow from US$ 210.89 million in 2024 to US$ 308.84 million by 2033, with a CAGR of 4.33% from 2025. Major growth drivers include an aging population, increasing osteoporosis rates, and favorable healthcare regulations. While bisphosphonates remain popular for their cost-effectiveness, biologics are expected to see the fastest growth. Government initiatives under Vision 2030 support local drug production and healthcare infrastructure, enhancing drug accessibility. However, challenges such as low adherence and rural access remain. Key market players include Amgen, Eli Lilly, and Pfizer. Saudi Arabian Osteoporosis Drugs Market Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Osteoporosis Drugs Market to Reach US$ 308.84 Million by 2033 - 4.33% CAGR Driven by Biologics and Aging Population" report has been added to Saudi Arabia Osteoporosis Drugs Market is expected to reach US$ 308.84 million by 2033 from US$ 210.89 million in 2024, with a CAGR of 4.33% from 2025 to 2033 Due to improved healthcare infrastructure, the Saudi Arabian market for osteoporosis medications is concentrated in urban areas like Riyadh, Jeddah, and Dammam, whereas rural areas have less access to experts, diagnostics, and treatment alternatives. Growing rates of osteoporosis, the quick uptake of biologics, and advantageous healthcare laws in a number of Saudi Arabian nations are the main causes of this expansion. While bisphosphonates continue to dominate in volume due to their cost effectiveness, the biologics segment is anticipated to grow at the quickest rate. Government programs under Vision 2030, which prioritize regional medication production and improved healthcare infrastructure, promote the pharmaceutical industry. Osteoporosis treatments are becoming more accessible and reasonably priced as a result of these initiatives, and both name brand and generic medications are essential in satisfying the rising calcitonin, parathyroid hormone analogs, selective estrogen receptor modulators (SERMs), and monoclonal antibodies are among the available treatments. Newer biologic medicines are steadily gaining traction because of their increased efficacy and better patient outcomes, even if bisphosphonates are still frequently administered. Despite progress, issues like poor drug adherence, low awareness in rural regions, and underdiagnosis still exist. Additionally, comprehensive nationwide screening programs and coordinated post fracture care are lacking. Reducing the long term economic cost of osteoporosis in the nation and improving treatment outcomes could be achieved by addressing these challenges through integrated care models, digital health technologies, and Factors Driving the Saudi Arabia Osteoporosis Drugs Market Growth Saudi Arabia's Aging Population Is GrowingBecause osteoporosis and aging are closely related, Saudi Arabia's aging population is a major factor driving up demand for osteoporosis medications. People are more susceptible to fractures, loss of bone density, and associated problems as they get older, especially those over?60. The need for long term therapeutic treatments as well as preventive measures is growing as a result of this demographic shift. More people are reaching the age range where osteoporosis becomes a major concern due to better healthcare and longer life expectancies. As a result, the incidence of osteoporosis is rising in areas with greater populations of elderly persons. In order to assist the aging population and lessen the health burden associated with fractures, this development emphasizes the urgent need for efficient drugs and healthcare Rates of Screening and DiagnosisEarly osteoporosis identification has increased throughout Saudi Arabia thanks to the availability of sophisticated diagnostic technologies including dual energy X ray absorptiometry (DEXA) and bone mineral density (BMD) scanning. These technologies are now widely used in hospitals and clinics, increasing screening accessibility for high risk populations, especially postmenopausal women. In order to encourage early testing and diagnosis, health authorities are aggressively promoting awareness and screening initiatives. Because of this, more people are being diagnosed with bone loss early on, when treatment can be most successful. The number of patients eligible for osteoporosis treatments has increased dramatically due to the increase in early detection, which has increased demand for pharmacological interventions and made it possible to control the condition more effectively over the long Initiated Medical ProgramsAs a national health issue, osteoporosis is being actively addressed by the Saudi Arabian government. It seeks to lower the frequency of fractures and enhance bone health outcomes through education programs, public health campaigns, and preventative measures. Osteoporosis screening and bone density monitoring are becoming more commonplace in national health programs, and access to therapies is being facilitated by drug reimbursement policies and subsidized treatment options. These programs are promoting earlier medical intervention and increasing treatment adherence. Additionally, by making strategic investments in public health, the government's Vision 2030 push for local pharmaceutical development and a larger healthcare infrastructure is bolstering the availability of osteoporosis medications and promoting long term market in the Saudi Arabia Osteoporosis Drugs Market Low Persistence and Adherence to TreatmentLow patient adherence and persistence with prescribed medication regimens is one of the main issues facing Saudi Arabia's osteoporosis management. A lack of immediate, apparent benefits, worries about long term health repercussions, or worries about adverse effects cause many patients to stop treatment too soon. Non-adherence is also influenced by cultural norms and a lack of knowledge about how osteoporosis progresses. Treatment results are harmed as a result, raising the risk of fractures and associated problems. Long term patient involvement is challenging for healthcare practitioners, particularly when patients need daily or weekly oral medication. Enhancing patient education, providing alternate dosage regimens, and incorporating follow up assistance may all contribute to increased adherence and improved population wide therapeutic Treatment Persistence and AdherencePoor patient perseverance and adherence to prescribed treatment regimens is one of the main issues facing osteoporosis care in Saudi Arabia. Due to worries about side effects, worries about long term health repercussions, or a lack of obvious, immediate advantages, many patients stop treatment too soon. Non-adherence is further exacerbated by cultural attitudes and a lack of knowledge regarding the progressive nature of osteoporosis. Treatment results suffer as a result, and the risk of fractures and associated complications rises. It can be challenging for healthcare professionals to stay in touch with patients over the long term, particularly when they need daily or weekly oral medication. Enhancing follow up assistance, providing alternate dose schedules, and improving patient education may all contribute to increased adherence and improved therapeutic efficacy for the general public. Company Analysis: Overview, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis Amgen Inc. Eli Lilly and Company F. Hoffmann La Roche AG GlaxoSmithKline Plc Merck & Co. Inc. Novartis AG Pfizer Inc. Teva Pharmaceutical Industries Ltd. UCB S.A. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $210.89 Million Forecasted Market Value (USD) by 2033 $308.84 Million Compound Annual Growth Rate 4.3% Regions Covered Saudi Arabia Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Saudi Arabia Osteoporosis Drugs Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product Type6.2 By Route of Administration6.3 By States7. Product Type7.1 Bisphosphonates7.2 Calcitonin7.3 Rank Ligand Inhibitor7.4 Parathyroid Hormone Therapy (PTH)7.5 Selective Estrogen Receptor Modulators (SERMs)7.6 Sclerostin Inhibitor7.7 Others8. Route of Administration8.1 Oral8.2 Injectable8.3 Others9. Top States9.1 Dhahran9.2 Riyadh9.3 Khobar9.4 Jeddah9.5 Dammam9.6 Others10. Value Chain Analysis11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Competition11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threats13. Pricing Benchmark Analysis13.1 Amgen Inc.13.2 Eli Lilly and Company13.3 F. Hoffmann-La Roche AG13.4 GlaxoSmithKline Plc13.5 Merck & Co. Inc.13.6 Novartis AG13.7 Pfizer Inc.13.8 Teva Pharmaceutical Industries Ltd.13.9 UCB S.A.14. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Osteoporosis Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data